Can-Fite BioPharma Ltd. Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

Finance Income (Tables)

12 Months Ended

Dec. 31, 2017

	Year ended December 31,
	2017			2016			2015
	USD
Finance expenses:

Bank commissions	$	28		$	27		$	20
Net change in fair value warrants exercisable into shares								113
Financial expenses from defined benefit plans		-			12			-
Net loss from exchange rate fluctuations		588			16			-
Other loss from long-term investment revaluation		5			-			-

		621			55			133
Finance income:

Interest income on bank deposits		(69	)		(89	)		(22	)
Net gain from exchange rate fluctuations		-			-			(84	)
Net change in fair value warrants exercisable into shares		(564	)		(285	)		-

	$	(633	)	$	(374	)	$	(106	)